A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

This is a Phase 1b/2, multicenter, open-label, basket study evaluating ACR-368, an adenosine triphosphate-competitive selective inhibitor of checkpoint kinase (CHK)1 and CHK2, as monotherapy and in combination with ultralow-dose gemcitabine (ULDG), in the treatment of subjects with histologically confirmed, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian or endometrial adenocarcinoma, or platinum-resistant urothelial carcinoma (hereafter referred to as ovarian, endometrial, and urothelial, respectively).